KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Rigel Pharmaceuticals (RIGL) EBT Margin: 2010-2025

Historic EBT Margin for Rigel Pharmaceuticals (RIGL) over the last 11 years, with Sep 2025 value amounting to 39.76%.

  • Rigel Pharmaceuticals' EBT Margin rose 1730.00% to 39.76% in Q3 2025 from the same period last year, while for Sep 2025 it was 40.53%, marking a year-over-year increase of 3807.00%. This contributed to the annual value of 10.24% for FY2024, which is 3171.00% up from last year.
  • According to the latest figures from Q3 2025, Rigel Pharmaceuticals' EBT Margin is 39.76%, which was down 32.59% from 58.99% recorded in Q2 2025.
  • Over the past 5 years, Rigel Pharmaceuticals' EBT Margin peaked at 58.99% during Q2 2025, and registered a low of -164.00% during Q1 2022.
  • Over the past 3 years, Rigel Pharmaceuticals' median EBT Margin value was 2.06% (recorded in 2023), while the average stood at 3.99%.
  • Within the past 5 years, the most significant YoY rise in Rigel Pharmaceuticals' EBT Margin was 11,396bps (2022), while the steepest drop was 21,494bps (2022).
  • Rigel Pharmaceuticals' EBT Margin (Quarterly) stood at -111.23% in 2021, then surged by 11,396bps to 2.73% in 2022, then tumbled by 67bps to 2.06% in 2023, then soared by 2,437bps to 26.43% in 2024, then spiked by 1,730bps to 39.76% in 2025.
  • Its EBT Margin was 39.76% in Q3 2025, compared to 58.99% in Q2 2025 and 21.58% in Q1 2025.